Abstract: The invention provides an apparatus and method for use in the treatment of substrates, the apparatus comprising housing means (1) having a first upper chamber having mounted therein a rotatably mounted cylindrical cage (2), a second lower chamber located beneath said cylindrical cage (2), at least one recirculation means, access means, pumping means, and a multiplicity of delivery means, whereby both the apparatus and the method find particular application in the cleaning of soiled textile fabrics.

Abstract: A door for providing access to a rotatably mounted drum of a cleaning apparatus, the door having a flow pathway for wash liquor and a multiplicity of solid particles and a separator, the separator being arranged to direct the multiplicity of solid particles from the flow pathway into the drum and wherein the separator is further arranged to direct a portion of the wash liquor from the flow pathway to a location other than into the drum.

Abstract: An apparatus for cleaning a soiled substrate using solid particulate material having a cleaning volume; a collecting volume; a pumping device having a pump inlet; and a circulation pathway by which solid particulate material and a transporting fluid can be transferred from the collecting volume to the cleaning volume via said pumping device. The apparatus further includes a flow regulating device disposed in the collecting volume and comprising a flow through enclosure defined by at least one wall, an enclosure outlet in communication with the pump inlet, at least one particle inlet orifice disposed at an underside of the flow through enclosure and configured to admit both solid particulate material and transporting fluid to the enclosure. The apparatus can further include at least one relatively smaller fluid inlet orifice configured only to admit transporting fluid to the flow through enclosure.

Abstract: The present invention provides a delivery system for active and functional ingredients. In particular, the delivery systems of the present invention find particular application in the delivery of active and functional ingredients, such as medicaments, pharmaceuticals, nutritional supplements, botanicals, cosmeceuticals etc. Further, the invention relates to a delivery system for oral or topical administration of such active and functional ingredients. The invention is a delivery system based on a particulate gel precursor that acts both as the bodying agent,as well as the dispersing and suspending agent in the formulation. By modifying the level of precursor and process conditions, a broad range of product consistencies can be achieved ranging from thin liquid suspension to firm or semi solid gel. The precursor gel is a particulate linear chain fuctan gel. Inulin is a preferred fructan.

Abstract: The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

Abstract: The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereofs, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).

Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).

Abstract: This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1 to R4, n W, X and Y are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).

Abstract: A process producing a pharmaceutical lozenge formulation comprising the steps of: 1) granulating a mixture of flurbiprofen and a bulking agent with a solution of a binding agent in a polar solvent to form granules; 2) melting a lozenge-forming composition; 3) mixing the granules with the molten lozenge-forming composition; 4) forming the resulting mixture into lozenges each containing a therapeutically effective amount of flurbiprofen.